Baxter commences BAX 855 Phase I trial in hemophilia A

Baxter International Inc. (NYSE: BAX) today announced the dosing of the first patients in a Phase I clinical trial of its lead investigational candidate, BAX 855, a longer-acting (PEGylated) form of a full-length recombinant factor VIII (rFVIII) protein. BAX 855 is based on Baxter's ADVATE [Antihemophilic Factor (Recombinant) Plasma/Albumin-Free Method] full-length rFVIII molecule and plasma/albumin-free (PAF) manufacturing process.

The Phase I trial is a prospective, open-label study that will assess the safety, tolerability and pharmacokinetics of BAX 855 in previously-treated patients aged 12 years or older with severe hemophilia A. When used for prophylaxis, Baxter's ADVATE requires patients to infuse every two to three days to reduce the occurrence of bleeding episodes. This Phase I trial is the first step in assessing whether BAX 855 can be infused less frequently.

"This trial is designed to provide new insights about our investigational longer-acting FVIII molecule, BAX 855, with the ultimate goal of improving care for patients living with hemophilia A," said Prof. Hartmut J. Ehrlich, M.D., vice president of global research and development in Baxter's BioScience business. "The Phase I results will serve as the foundation for advancing this important program through clinical development and determining whether BAX 855 can offer a treatment regimen requiring fewer infusions than ADVATE."

Source:

Baxter International Inc.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Baxter International Inc.. (2019, June 18). Baxter commences BAX 855 Phase I trial in hemophilia A. News-Medical. Retrieved on February 25, 2021 from https://www.news-medical.net/news/20120105/Baxter-commences-BAX-855-Phase-I-trial-in-hemophilia-A.aspx.

  • MLA

    Baxter International Inc.. "Baxter commences BAX 855 Phase I trial in hemophilia A". News-Medical. 25 February 2021. <https://www.news-medical.net/news/20120105/Baxter-commences-BAX-855-Phase-I-trial-in-hemophilia-A.aspx>.

  • Chicago

    Baxter International Inc.. "Baxter commences BAX 855 Phase I trial in hemophilia A". News-Medical. https://www.news-medical.net/news/20120105/Baxter-commences-BAX-855-Phase-I-trial-in-hemophilia-A.aspx. (accessed February 25, 2021).

  • Harvard

    Baxter International Inc.. 2019. Baxter commences BAX 855 Phase I trial in hemophilia A. News-Medical, viewed 25 February 2021, https://www.news-medical.net/news/20120105/Baxter-commences-BAX-855-Phase-I-trial-in-hemophilia-A.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
You might also like... ×
Gilead to boost price of new hepatitis c drug